Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy
Citations
63 citations
51 citations
41 citations
Cites background from "Toxicities of systemic agents in sq..."
...Targeted therapy approved for use in HNSCC is the EGFR inhibitor, cetuximab (Saba et al. 2017)....
[...]
...inhibiting downstream signaling cascades (Saba et al. 2017)....
[...]
...Cetuximab competitively antagonizes binding of epidermal growth factor (EGF) and transforming growth factor α (TGFα) to EGFR, thereby inhibiting downstream signaling cascades (Saba et al. 2017)....
[...]
39 citations
Cites background from "Toxicities of systemic agents in sq..."
...Hematologic toxicity, ototoxicity, and renal failure were only determined in the population who received cisplatin as radiosensitizer, because cetuximab is not myelosuppressive and less nephrotoxic and neurotoxic than cisplatin.(22) Overall dose-limiting toxicity (including neutropaenia, renal failure,...
[...]
27 citations
References
6,318 citations
"Toxicities of systemic agents in sq..." refers background in this paper
...…resulting in FDA approval of both agents (Ferris et al., 2016; Seiwert et al., 2016) Similarly, clinical trials are ongoing to evaluate a potential role for ipilimumab, a CTLA-4 antagonist, in head and neck cancer, as it already has been approved for the treatment of melanoma (Larkin et al., 2015)....
[...]
4,705 citations
4,177 citations
3,246 citations
"Toxicities of systemic agents in sq..." refers background or result in this paper
...Both these agents have recently been studied in clinical trials with encouraging results, resulting in FDA approval of both agents (Ferris et al., 2016; Seiwert et al., 2016) Similarly, clinical trials are ongoing to evaluate a potential role for ipilimumab, a CTLA-4 antagonist, in head and neck…...
[...]
...…other patient reported quality of life meaures, including dyspnea, insomnia, pain, etc. was actually noted o be nearly stable or slightly improved, compared to the standard herapy group, which reported clinically meaningful worsening of hysical, role, and social functioning (Ferris et al., 2016)....
[...]
...Early data already published suggests that immune checkpoint inhibitors might be superior to investigator’s choice medication in the second-line recurrent/metastatic disease setting (Ferris et al., 2016)....
[...]
2,940 citations